China ropes in more countries for its COVID-19 vaccine trials


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ china-ropes-more-countries-covid19-vaccine-trials
In recent weeks, officials from Mexico, Bangladesh and Pakistan have been quoted in the media, stating about the trials as a means to gain future access to approved vaccines

China has roped in more than a dozen countries to conduct the final phase trials of its experimental COVID-19 vaccines, as it looks to stay ahead in the international race to immunize the global population as part of its charm offensive to gain goodwill.

Across the world, in many countries, including Peru, Argentina, Brazil, Bahrain, the UAE, Egypt, Pakistan, Turkey, Morocco, Saudi Arabia, Bangladesh, Indonesia, and Russia, thousands of people have been injected with experimental vaccines made by China's three front-running vaccine makers or soon will be, Hong Kong-based South China Morning Post reported on Tuesday quoting company, government statements, and media reports.

For some of these countries at least, approving the final phases of clinical trials has been viewed as a means of securing early access to vaccines, because several wealthy nations have already bought doses pending approval and a World Health Organization (WHO) mechanism.

In recent weeks, officials from Mexico, Bangladesh, and Pakistan have been quoted in the media, stating about the trials as a means to gain future access to approved vaccines.

On September 25, a Chinese health official said the WHO had given its backing to China's emergency use of experimental vaccines even though clinical trials have not yet been completed.

Zheng Zhongwei, head of medical science development at the National Health Commission told media that the WHO gave its blessings to China for its emergency use of vaccines in late June.

According to Zheng, the commission proposed emergency use of the vaccines in mid-June to protect people in high-risk occupations such as frontline health workers, border officials, and overseas workers. The vaccines had still to complete phase three of clinical trials but the State Council approved the proposal on June 24.

"After the approval, on June 29, we had a communication meeting with the relevant representatives of the WHO office in China, and obtained understanding and support from the WHO," the Post quoted Zheng as saying.

He said the approval strictly abided by China's vaccine and pharmaceutical laws and used WHO standards as a guide, adding that there were no severe adverse events from the injections.

The WHO faced stringent criticism especially from US President Donald Trump who accused it of being a puppet of China for not acting in time to halt the spread of the COVID-19 when it broke out in the Chinese city of Wuhan in December last year. Trump has also pulled the US out of the WHO.

In his address to the UN General Assembly on September 23, Trump also attacked the WHO saying that it is "virtually controlled by China".

Last week, Chairman Yang Xiaoming of China National Biotec Group, which had obtained approval to start phase 3 trials for its coronavirus vaccine candidates in the United Arab Emirates said 350,000 people had been injected with the experimental vaccines under the scheme.

Yang Sheng, the Deputy Director of the National Medical Products Administration's drug registration bureau, said four China-developed COVID-19 vaccines have begun the final stage of human trials overseas after obtaining approval from foreign authorities.

China has been focusing on developing five types of vaccines, and each method has at least one entering clinical trials. In total, 11 vaccine candidates are in different stages of testing, Yang was quoted by the state-run China Daily.

Zheng said China's annual capacity to make COVID-19 vaccines was expected to reach 610 million doses this year and 1 billion doses by 2021. He offered no details on how the doses would be distributed.

Facing global adversity over the mass spread of the coronavirus, China plans to have a diplomatic offensive offering its vaccines especially to several smaller countries at affordable costs

Tags : #China #COVID-19 #Vaccine #Trials

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026